Back to Results

Athersys Inc (ATHXQ)

Athersys, Inc. is an OTC Markets-listed common stock of a clinical-stage biotechnology company focused on regenerative medicine. The company’s principal product candidate is MultiStem, an allogeneic stem cell therapy being studied for potential use across neurological, inflammatory and immune, cardiovascular, and other critical care indications. Founded in 1995 and based in Cleveland, Ohio, Athersys operated as a development-stage biotech issuer rather than a commercial drug company. On January 5, 2024, the company and its affiliates filed for Chapter 11 bankruptcy, and that case was later converted to Chapter 7 on September 24, 2024.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap
OTC-ATHX.Q
Not available
Not available
Not available
Weak
0.0%
November 19, 2026
0.061 K
Valuation • Fair Value

Athersys Inc (OTC-ATHX.Q) Fair Value by Valuation Model

No usable valuation estimate is currently available for Athersys Inc (OTC-ATHX.Q); fair value and analyst target coverage statuses are shown explicitly below.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

No usable valuation estimate is currently available for Athersys Inc (OTC-ATHX.Q). Fair value and the analyst target remain visible as coverage-status fields and should not be read as valuation signals while unavailable.

Profitability • Growth

Profitability & Growth for Athersys Inc (OTC-ATHX.Q)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

3 M

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Athersys Inc (OTC-ATHX.Q) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Athersys Inc (OTC-ATHX.Q)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Athersys Inc (OTC-ATHX.Q). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Athersys Inc (OTC-ATHX.Q)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 19, 2026

Days to Earnings

63

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Athersys Inc (OTC-ATHX.Q), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Athersys Inc (OTC-ATHX.Q) Stock Forecast & Technical Outlook

Review Athersys Inc (OTC-ATHX.Q) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Sell

The 15-minute technical read for Athersys Inc (OTC-ATHX.Q) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Sell

The 1-hour technical read for Athersys Inc (OTC-ATHX.Q) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Sell

The daily technical read for Athersys Inc (OTC-ATHX.Q) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Athersys Inc (OTC-ATHX.Q) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Athersys Inc (OTC-ATHX.Q) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Athersys Inc (OTC-ATHX.Q)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Athersys Inc (OTC-ATHX.Q) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Athersys Inc (OTC-ATHX.Q) Stock FAQ

Data-supported answers about Athersys Inc (OTC-ATHX.Q), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
Not available
No reliable estimate from the currently supported inputs
Financial Health
Weak
Current financial-health read

A reliable fair value estimate is not currently available for Athersys Inc (OTC-ATHX.Q). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

The current financial health read for Athersys Inc (OTC-ATHX.Q) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Athersys Inc (OTC-ATHX.Q) is November 19, 2026.

The latest available data indicates no current dividend yield for Athersys Inc (OTC-ATHX.Q).

The current market capitalization listed for Athersys Inc is 0.061 K.

The ticker symbol for Athersys Inc is OTC-ATHX.Q, and the stock is listed on OTC Markets.

Athersys Inc (OTC-ATHX.Q) is listed on OTC Markets.

Similar Biotechnology Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 463.9 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 203.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 183.1 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.1 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 77.349 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 60.916 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 58.137 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 49.779 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.993 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.577 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.029 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.916 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.582 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.769 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.287 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.073 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.38 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.286 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 16.267 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 15.197 B